<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02590809</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2015/14</org_study_id>
    <nct_id>NCT02590809</nct_id>
  </id_info>
  <brief_title>Hypertrophic Cardiomyopathy Symptom Release by BX1514M</brief_title>
  <acronym>Light-CARMIDO</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypertrophic cardiomyopathy (HCM) is the most frequent genetic cardiac disease characterized&#xD;
      by an asymmetric hypertrophic. In two third of patients, an obstruction to blood ejection is&#xD;
      observed within the left ventricle which is named left ventricular outflow tract obstruction&#xD;
      (LVOTO). This phenomenon can occur at rest or during exercise and is associated with symptoms&#xD;
      such as dyspnea, dizziness or chest pain that can significantly limit day life adaptation. To&#xD;
      now, medical or interventional treatments such as betablocacker, calcium blockers or septal&#xD;
      alcoholisation or surgery present with a limited efficiency. Recent studies from&#xD;
      investigators group revealed new concepts about the role of venous return to the LVOTO.&#xD;
      Therefore the investigators hypothesis that BX1514M generating a venous vascular&#xD;
      constriction, could improve symptoms of HCM patients by reducing LVOTO.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 7, 2015</start_date>
  <completion_date type="Actual">July 6, 2016</completion_date>
  <primary_completion_date type="Actual">July 6, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline at day 15 of covered distance during the 6 minutes walk distance test (6MWT)</measure>
    <time_frame>Day 15</time_frame>
    <description>In meters</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Covered distance during the 6 minutes walk distance test (6MWT)</measure>
    <time_frame>Day 30</time_frame>
    <description>In meters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exercise echocardiography with measures of blood pressures in the rest and in the effort</measure>
    <time_frame>Day 1, day 15, day 30</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Hypertrophic Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>Treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>20 patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment BX1514M</intervention_name>
    <description>X mg x 3 /day of BX1514M for 15 days. Dosage will be then adapted, depending on symptoms release and walk distance test results for another 15 days period.</description>
    <arm_group_label>Treatment group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be given for 30 days</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Walk distance test</intervention_name>
    <description>Walk distance test during 6 minutes</description>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_label>Treatment group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Exercise echocardiography</intervention_name>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_label>Treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with a typical or atypical hypertrophic cardiomyopathy (HCM) confirmed by&#xD;
             imaging modalities (echo and MRI) and/or genetic tests or a relative history of HCM&#xD;
&#xD;
          -  Left ventricular obstruction during exercise on treadmill (above 50 mmHg)&#xD;
&#xD;
          -  Positive response to leg lifting test (obstruction reduction above 20 mmHg) at rest or&#xD;
             in early recovery phase&#xD;
&#xD;
          -  Daily symptoms as shortness of breath during exercise (NYHA2-3), non coronary chest&#xD;
             pain, dizziness&#xD;
&#xD;
          -  Correct ultrasound windows quality&#xD;
&#xD;
          -  Sinus rhythm&#xD;
&#xD;
          -  Optimal medical treatment&#xD;
&#xD;
          -  For women, pregnancy test or contraception&#xD;
&#xD;
          -  Written consent form obtained&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous treatment by BX1514M&#xD;
&#xD;
          -  Extra-cardiac pathology with life expectancy below than 1 year&#xD;
&#xD;
          -  No capability of consent form written&#xD;
&#xD;
          -  Pregnancy women&#xD;
&#xD;
          -  Secondary hypertension hypertrophy, secondary valvular disease hypertrophy&#xD;
&#xD;
          -  Permanent atrial fibrillation&#xD;
&#xD;
          -  Severe ventricular arrhythmia without Implantable Cardioverter Defibrillator (ICD)&#xD;
&#xD;
          -  Severe coronary disease&#xD;
&#xD;
          -  Severe non stabilized hypertension&#xD;
&#xD;
          -  Severe cardiopathy (ejection fraction below 40% or demonstrated elevated end diastolic&#xD;
             pressure or pulmonary pressure above 60 mmHg)&#xD;
&#xD;
          -  Bradycardia&#xD;
&#xD;
          -  Narrow angle glaucoma&#xD;
&#xD;
          -  Vascular prethrombotic diseases&#xD;
&#xD;
          -  Vascular spams&#xD;
&#xD;
          -  Thyrotoxicosis&#xD;
&#xD;
          -  Pheochromocytoma&#xD;
&#xD;
          -  Severe renal failure (&lt;30ml/mn)&#xD;
&#xD;
          -  Patients at risk of urinary retention secondary to prostatic severe disease&#xD;
&#xD;
          -  Raynaud's disease&#xD;
&#xD;
          -  Non selective Monoamine Oxidase Inhibitors (MAOIs), iproniazid, nialamide or&#xD;
             ephedrine, methylphenidate, phenylephrine, pseudoephedrine or digitalic&#xD;
&#xD;
          -  Procedures modifying the peripheral venous return&#xD;
&#xD;
          -  Participation to other research protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>St√©phane LAFITTE, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Bordeaux</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU de Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <study_first_submitted>October 27, 2015</study_first_submitted>
  <study_first_submitted_qc>October 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 29, 2015</study_first_posted>
  <last_update_submitted>February 8, 2017</last_update_submitted>
  <last_update_submitted_qc>February 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Left ventricular obstruction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Cardiomyopathy, Hypertrophic</mesh_term>
    <mesh_term>Hypertrophy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

